Alpha 2.0
Login Register
» Authors » Kenneth Lasseter

Kenneth Lasseter

Explore the profile of Kenneth Lasseter including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 490
Followers 0
Related Specialties
Pharmacology
Psychiatry
Endocrinology
Top 10 Co-Authors
Thomas Marbury
Stacy Dilzer
Li Chen
Wei Zeng
Mary Corcoran
Arthur Bergman
John A Wagner
James Ermer
John Wagner
Patrick Martin
Published In
J Clin Pharmacol
Clin Pharmacokinet
Clin Drug Investig
Drug Metab Dispos
Biopharm Drug Dispos
Affiliations
Soon will be listed here.
Recent Articles
1.
Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist
Nussbaum J, Hussain A, Min K, Marbury T, Lasseter K, Stoch S, et al.
J Clin Pharmacol . 2022 Jun; 62(11):1435-1444. PMID: 35656754
Gefapixant, a P2X3 receptor antagonist, has demonstrated efficacy in patients with refractory or unexplained chronic cough. We investigated the effect of renal impairment (RI) on the pharmacokinetics (PK) of gefapixant...
2.
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin
Bhagunde P, Colon-Gonzalez F, Liu Y, Wu J, Sherrie Xu S, Garrett G, et al.
Br J Clin Pharmacol . 2019 Dec; 86(5):944-957. PMID: 31856304
Aims: Two phase 1, open-label studies were conducted to investigate the effect of renal impairment (RI) and organic anion transporter (OAT) inhibition on pharmacokinetics (PK) and safety of relebactam (REL)...
3.
Effects of Maribavir on P-Glycoprotein and CYP2D6 in Healthy Volunteers
Song I, Ilic K, Murphy J, Lasseter K, Martin P
J Clin Pharmacol . 2019 Aug; 60(1):96-106. PMID: 31385617
Maribavir is an investigational drug being evaluated in transplant recipients with cytomegalovirus infection. To understand potential drug-drug interactions, we examined the effects of multiple doses of maribavir on cytochrome P450...
4.
Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis
Zomorodi K, Chen D, Lee L, Lasseter K, Marbury T
J Clin Pharmacol . 2019 Mar; 59(8):1120-1129. PMID: 30865315
Solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting effects, is renally excreted ∼90% unchanged within 48 hours. Effects of renal impairment and hemodialysis on the pharmacokinetics and...
5.
Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
Duchin K, Senaldi G, Warren V, Marbury T, Lasseter K, Zahir H
Clin Drug Investig . 2018 Sep; 38(11):1001-1009. PMID: 30171457
Background And Objectives: Mirogabalin is an αδ ligand being developed to treat neuropathic pain. A small fraction of mirogabalin is metabolized by the liver, where hepatic impairment may affect exposure....
6.
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment
Mogalian E, Brainard D, Osinusi A, Moorehead L, Murray B, Ling K, et al.
Clin Pharmacokinet . 2018 Mar; 57(11):1449-1457. PMID: 29520729
Background: The pharmacokinetics and safety of velpatasvir, a potent pangenotypic hepatitis C virus NS5A inhibitor, were evaluated in two hepatic impairment studies: a phase I study in hepatitis C virus-uninfected...
7.
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
Marbury T, Flint A, Jacobsen J, Karsbol J, Lasseter K
Clin Pharmacokinet . 2017 Mar; 56(11):1381-1390. PMID: 28349386
Background: The pharmacokinetics and tolerability of semaglutide, a once-weekly human glucagon-like peptide-1 analog in development for the treatment of type 2 diabetes mellitus, were investigated in subjects with/without renal impairment...
8.
Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink
Ermer J, Corcoran M, Lasseter K, Martin P
Ther Drug Monit . 2016 Sep; 38(6):769-776. PMID: 27661399
Background: This open-label, crossover study examined lisdexamfetamine dimesylate (LDX) and D-amphetamine pharmacokinetics in healthy adults after administration of an intact LDX capsule or after the capsule was emptied into orange...
9.
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus
Vajda E, Logan D, Lasseter K, Armas D, Plotkin D, Pipkin J, et al.
Diabetes Obes Metab . 2016 Aug; 19(1):24-32. PMID: 27501510
Aim: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of a novel, oral glucagon receptor antagonist, LGD-6972, in healthy subjects and subjects with type 2...
10.
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies
Roberts T, Kokai-Kun J, Coughlin O, Lopez B, Whalen H, Bristol J, et al.
Clin Drug Investig . 2016 Jun; 36(9):725-734. PMID: 27283946
Background: SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous β-lactam antibiotics like cephalosporins. SYN-004 is intended to degrade residual antibiotics excreted into the...